Labcorp Holdings Inc.

NYSE:LH

Medical - Diagnostics & Research

Healthcare
$370.78 -1.33%

-$3.46 today

Market cap
$30.11B
Beta
0.88
P/E (TTM)
22.4
EPS (TTM)
$11.44
Dividend yield
1.12%
52W Low $241.81High $293.72

Volume 0.69M

Average 0.63M

LH EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Labcorp Holdings Inc.NYSE: LH

EBITDA · Q2 FY2026 · quarter ended Jun 2026

EBITDA grows in line with its trailing trend

Q2 FY2026 EBITDA of $620.9M rose 16.7% year over year, ahead of the +15.0% change in trailing-twelve-month EBITDA. Sequentially, it rose 13.3% from the prior quarter. Over 3 fiscal years it compounded at +1.0% a year.

Context

  • EBITDA amounted to 14.4% of revenue in FY2025, up 0.5 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 8 analysts of $2.74B (+36.0%) for the fiscal year ending Dec 2026, a step up from the +11.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$620.9M+13.3% QoQ
Last fiscal yearDec 2025
$2.01B+11.1% YoY
LTMJun 2026
$2.15B+15.0% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+16.7%+24.3%+7.6 pp
1 year+11.1%+36.0%+24.9 pp
3-year CAGR+1.0%+15.1%+14.1 pp
5-year CAGR+11.6%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
2.01B USD
Year-over-year change
+11.1%
4-year CAGR
-14.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How LH compares with its peers on the latest reported figures

  • LH's LTM Jun 2026 EBITDA of $2.15B is the 3rd highest of the 7 companies compared; the peer median is $262.34M.
  • Its year-over-year change of +15.0% is the 2nd highest of 7, against a peer median of +3.5%.
  • EBITDA amounts to 15.0% of revenue for LH, versus a peer median of 28.6%.
LH Competitors Peer median
EBITDA for LH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TMOThermo Fisher Scientific Inc.LTM Sep 2026$11.24B -0.8%-1.3%23.7%
DGXQuest Diagnostics IncorporatedLTM Sep 2026$2.3B +7.7%+6.4%19.4%
LHLabcorp Holdings Inc.LTM Jun 2026$2.15B +15.0%+1.0%15.0%
QGENQiagen N.V.LTM Jun 2026$703.39M -1.6%-2.7%33.5%
NTRANatera, Inc.LTM Jun 2026-$178.71M +15.6%—6.6%
GRALGRAIL, Inc.LTM Jun 2026-$374.1M +10.8%—226.4%
GHGuardant Health, Inc.LTM Sep 2026-$441.45M -24.7%—34.5%
Peer median (excluding LH) $262.34M+3.5%-1.3%28.6%

Competitors are the stored peer set for LH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue13.14B11.86B12.16B13.01B13.95B
Cost of Revenue8.14B8.16B8.8B9.38B10.22B
Gross Profit4.99B3.71B3.36B3.62B3.73B
Gross Margin38.0%31.3%27.7%27.9%26.8%
Research & Development002M00
Selling, General & Admin1.69B2B2.02B2.23B2.22B
Operating Expenses1.94B2.27B2.64B2.54B2.22B
Depreciation & Amortization577M537.2M577.3M643.5M681.1M
EBITDA3.68B1.95B1.35B1.81B2.01B
EBITDA Margin28.0%16.5%11.1%13.9%14.4%
Operating Income3.05B1.44B725.6M1.09B1.52B
Operating Margin23.2%12.1%6.0%8.4%10.9%
Interest Income000015.2M
Interest Expense211.8M179.8M199.6M208.3M224.1M
Other Income / Expenses(161M)(199.1M)(156.7M)(127.2M)(408.7M)
Income Before Tax2.89B1.24B568.9M959.5M1.11B
Pre-Tax Margin22.0%10.4%4.7%7.4%7.9%
Income Tax Expense690M233.9M188.5M212.4M229.8M
Net Income2.38B1.28B418M746M876.5M
Net Margin18.1%10.8%3.4%5.7%6.3%
EPS (Basic)24.5814.044.808.8910.54
EPS (Diluted)24.3813.964.778.8410.46
Weighted Avg Shares96.7M91.1M87.1M83.9M83.2M
Weighted Avg Shares (Diluted)97.5M91.6M87.6M84.4M83.8M

Labcorp Holdings Inc.

NYSE:LH

Intrinsic Alpha fair value

Locked

Current Price

$370.78

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.